Skip to main content
Jaffer Ajani, MD, Oncology, Houston, TX

JafferA.AjaniMD

Oncology Houston, TX

Professor of Medicine, University Tex Houston

Are you Dr. Ajani?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Summary

  • Dr. Jaffer Ajani, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is a Professor of Medicine at University Tex Houston.

Education & Training

  • Indira Gandhi Medical College
    Indira Gandhi Medical CollegeClass of 1971

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2024 - 2026
  • WA State Medical License
    WA State Medical License 2024 - 2026
  • AL State Medical License
    AL State Medical License 2024 - 2025
  • GA State Medical License
    GA State Medical License 2024 - 2025
  • LA State Medical License
    LA State Medical License 1977 - 2025
  • LA State Medical License
    LA State Medical License 2024 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • New Insights into Biology, Origin of Deadly Stomach and Esophageal Cancers
    New Insights into Biology, Origin of Deadly Stomach and Esophageal CancersOctober 27th, 2022
  • Immunotherapy Is Now the First Choice for Esophageal Cancer
    Immunotherapy Is Now the First Choice for Esophageal CancerMay 31st, 2022
  • BMS’ Opdivo Gets Late-Stage Oesophageal Cancer Nod from FDA
    BMS’ Opdivo Gets Late-Stage Oesophageal Cancer Nod from FDAMay 29th, 2022
  • Join now to see all

Grant Support

  • Common Stem Cell of Origin for Junctional and Gastric AdenocarcinomaUNIVERSITY OF HOUSTON2022–2027